Codexis (NASDAQ:CDXS) Stock Rating Reaffirmed as “Overweight” by Stephens

Codexis (NASDAQ:CDXS – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at Stephens in a research note issued to investors on Monday, Benzinga reports. They presently have a $5.00 price target on the biotechnology company’s stock. Stephens‘s price target points to a potential upside of 331.03% from the company’s previous close.

Several other equities analysts have also commented on CDXS. Piper Sandler lowered their price objective on Codexis from $9.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, August 17th. Wall Street Zen raised shares of Codexis from a “sell” rating to a “hold” rating in a research report on Saturday. Benchmark reaffirmed a “hold” rating on shares of Codexis in a research report on Thursday, August 20th. Finally, Weiss Ratings upgraded shares of Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 23rd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $6.00.

Check Out Our Latest Analysis on CDXS

Codexis Price Performance

Shares of NASDAQ:CDXS opened at $1.16 on Monday. Codexis has a 52-week low of $0.90 and a 52-week high of $2.98. The firm has a market capitalization of $127.03 million, a P/E ratio of -5.80 and a beta of 2.38. The stock has a 50 day moving average price of $1.29 and a 200-day moving average price of $1.78. The company has a debt-to-equity ratio of 1.03, a quick ratio of 2.99 and a current ratio of 3.06.

Codexis (NASDAQ:CDXS – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.02. The company had revenue of $19.26 million for the quarter, compared to analyst estimates of $18.72 million. Codexis had a negative return on equity of 45.54% and a negative net margin of 21.77%. As a group, equities research analysts anticipate that Codexis will post -0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Codexis

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Codexis during the 2nd quarter valued at about $16,463,000. Nantahala Capital Management LLC bought a new stake in Codexis during the 2nd quarter valued at about $8,189,365. Man Group plc purchased a new position in Codexis in the second quarter worth about $1,278,000. Assenagon Asset Management S.A. raised its holdings in Codexis by 70.2% in the second quarter. Assenagon Asset Management S.A. now owns 1,278,206 shares of the biotechnology company’s stock worth $2,889,000 after buying an additional 527,036 shares during the last quarter. Finally, Stonepine Capital Management LLC purchased a new position in Codexis in the second quarter worth about $247,836. Institutional investors own 78.54% of the company’s stock.

Codexis Company Profile

(Get Free Report)

Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.

Further Reading

Analyst Recommendations for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.